| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 190 | 330 | 330 | 260 | 410 |
| Sales Growth | -42.42% | unch | +26.92% | -36.59% | +51.85% |
| Net Income | -1,820 | -1,600 | -1,200 | -1,830 | -1,720 |
| Net Income Growth | -13.75% | -33.33% | +34.43% | -6.40% | +27.73% |
Igc Pharma Inc
(IGC)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
IGC Pharma Inc. develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. IGC Pharma Inc., formerly known as India Globalization Capital Inc., is based in POTOMAC, Md.
Fiscal Year End Date: 03/31